Good MorningEquity markets started the year on a weak footing, opening with a slight gain but falling after the opening to leave most major indices in red at the session's end. However, the losses were small, and the market remains above critical support targets, so a deeper decline appears unlikely. Friday's session will likely be another with light volume and indeterminate market action.
Next week will be a hurdle for the market. The December labor data is due and will likely be strong. The takeaway will be how strong, and whether the FOMC can be relied on for additional interest rate cuts. If not, the market may sell off in response, but the move will be short-lived. The critical detail is that healthy labor markets support consumer spending, which is the primary driver of the U.S. economy. In that scenario, the outlook for consumer spending and S&P 500 profits will put a floor in the sell-off, and a higher high will come soon for the S&P 500. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Technology | |
Warren Buffett, the legendary Oracle of Omaha and arguably the most famous investor to have ever lived, owes a great deal of his success to his buy-and-hold approach that tends to focus on blue-chip dividend stocks. Berkshire Hathaway's huge positions in dividend stalwarts like Bank of America Cor... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Technology | |
Legacy, product-based software technology is quickly becoming obsolete. Not only is the cloud the dominant force in technology today, but AI is also rapidly advancing, altering how software technology is used. Today, we look at three once-powerful legacy software technology companies reemerging as... Read the Full Story |
|
Technology | |
Cybersecurity is a hot topic with the pace of attacks growing, the costs multiplying, and opportunities abundant for cybersecurity companies. Estimated to triple by 2027, the cybersecurity market will top $10.50 trillion, with much spending concentrated on a few names. Leading providers like Palo ... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Communication Services | |
The stock market softened as 2024 ended, with equities retreating amid a more cautious Federal Reserve and lingering inflation concerns. However, while some investors are hesitating, others see this dip as a chance to buy strong stocks at attractive prices.
An easy way to find opportunities? Watc... Read the Full Story |
|
Consumer Discretionary | |
Overall, 2024 was a year of underperformance when it comes to retail stocks. The SPDR S&P Retail ETF (NYSEARCA: XRT) finished the year with a total return of just under 12%. That is approximately half the return generated by the S&P 500 Index. However, there were several standouts in the i... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Technology | |
The days of individual price action in the financial market are long gone, as one asset class like stocks, bonds, or commodities used to move independently without much pressure from others. However, the past few decades have changed all that, especially as more participants join the stock market ... Read the Full Story |
|
Communication Services | |
The streaming giant Netflix (NASDAQ: NFLX) recently achieved massive success in its journey to enter the live sports market. The communication services company hosted two National Football League (NFL) games on Christmas Day, breaking records. The average audience for the games was over 26 milli... Read the Full Story |
|
Industrials | |
According to many of the professional and biggest value investors in the stock market today, there are stocks that are easy to spot early on before they become industry leaders. This is paramount to wealth compounding since, as these companies grow from middle-sized businesses to industry leaders,... Read the Full Story |
|
Markets | |
Volume is what drives the entire market, and that is a fact that often gets lost in the sea of indicators, patterns, and trend lines that dominate today’s concept of analysis. However, most investors fail to realize that these indicators and patterns are nothing more than price action recogn... Read the Full Story |
|
Consumer Discretionary | |
Tesla Inc (NASDAQ: TSLA) shares are rounding out a phenomenal year, delivering gains as much as 250% off the back of decent performance and a favorable macro environment. For example, much of this year’s rally has been fueled by strong investor sentiment following geopolitical developments... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas. | | View Today's Stock Pick |
|
